Nicotinamide N‑methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression‑free and overall survival times

Zhou,Weimin; Gui,Ming; Zhu,Min; Long,Zhi; Huang,Lihua; Zhou,Jun; He,Leye; Zhong,Kuangbiao

doi:10.3892/ol.2014.2287

Nicotinamide N‑methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression‑free and overall survival times

Authors:
- Weimin Zhou
- Ming Gui
- Min Zhu
- Zhi Long
- Lihua Huang
- Jun Zhou
- Leye He
- Kuangbiao Zhong
View Affiliations

Affiliations: Department of Urology, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Nephrology, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Molecular Biology Research Center, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, P.R. China, Center for Medical Experiments, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: June 26, 2014 https://doi.org/10.3892/ol.2014.2287
Pages: 1175-1180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nicotinamide N‑methyltransferase (NNMT) has been identified to be associated with tumorigenesis and the malignant transformation of numerous types of cancer. The aim of the present study was to explore the expression and prognostic significance of NNMT in prostate cancer (PCa). Immunohistochemical NNMT expression was examined in 26 cases of benign prostate hyperplasia (BPH), 18 cases of high‑grade prostatic intraepithelial neoplasia (HGPIN) and 120 cases of PCa. While rarely expressed in BPH (8/26 cases; 30.8%), NNMT was found to be significantly upregulated in HGPIN (15/18 cases; 83.3%) and PCa (77/120 cases; 64.2%). Clinicopathological analysis revealed that NNMT expression was negatively correlated with Gleason score (P<0.001). Furthermore, Kaplan‑Meier survival curves revealed that high NNMT expression was associated with prolonged progression‑free survival (PFS) and overall survival (OS) times in patients with advanced PCa. Multivariate analysis showed that NNMT was an independent prognostic marker of PFS and OS in patients with advanced PCa. The results of the present study suggested that NNMT may contribute to the development of PCa and may potentially be a favorable prognostic marker for the survival of patients with advanced PCa.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
3	Ross RW, Oh WK, Xie W, et al: Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 26:842–847. 2008.
4	Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490. 2004.
5	Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 10:33–39. 2004.
6	Choueiri TK, Xie W, D’Amico AV, et al: Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 115:981–987. 2009.
7	Bickers B and Aukim-Hastie C: New molecular biomarkers for the prognosis and management of prostate cancer - the post PSA era. Anticancer Res. 29:3289–3298. 2009.
8	Shariat SF, Karam JA and Roehrborn CG: Blood biomarkers for prostate cancer detection and prognosis. Future Oncol. 3:449–461. 2007.
9	Aksoy S, Szumlanski CL and Weinshilboum RM: Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem. 269:14835–14840. 1994.
10	Rini J, Szumlanski C, Guerciolini R and Weinshilboum RM: Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta. 186:359–374. 1990.
11	Tomida M, Mikami I, Takeuchi S, Nishimura H and Akiyama H: Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol. 135:1223–1229. 2009.
12	Roessler M, Rollinger W, Palme S, et al: Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res. 11:6550–6557. 2005.
13	Sartini D, Pozzi V, Renzi E, et al: Analysis of tissue and salivary nicotinamide N-methyltransferase in oral squamous cell carcinoma: basis for the development of a noninvasive diagnostic test for early-stage disease. Biol Chem. 393:505–511. 2012.
14	Sartini D, Muzzonigro G, Milanese G, et al: Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys. 65:473–483. 2013.
15	Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 85:200–206. 1993.
16	Markert JM, Fuller CM, Gillespie GY, et al: Differential gene expression profiling in human brain tumors. Physiol Genomics. 5:21–33. 2001.
17	Jang JS, Cho HY, Lee YJ, Ha WS and Kim HW: The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res. 14:491–499. 2004.
18	Xu J, Moatamed F, Caldwell JS, et al: Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 88:4990–4996. 2003.
19	Kim J, Hong SJ, Lim EK, et al: Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res. 28:202009.
20	Tang SW, Yang TC, Lin WC, et al: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 32:138–145. 2011.
21	Kim HC, Mofarrahi M, Vassilakopoulos T, et al: Expression and functional significance of nicotinamide N-methyl transferase in skeletal muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 181:797–805. 2010.
22	Mateuszuk Ł, Khomich TI, Słomińska E, et al: Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis. Pharmacol Rep. 61:76–85. 2009.
23	Williams AC and Ramsden DB: Autotoxicity, methylation and a road to the prevention of Parkinson’s disease. J Clin Neurosci. 12:6–11. 2005.
24	Sakr WA and Partin AW: Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology. 57:115–120. 2001.
25	Emanuelli M, Santarelli A, Sartini D, et al: Nicotinamide N-Methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol. 25:15–20. 2010.
26	Zhang J: Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked? Bioessays. 25:808–814. 2003.
27	Jung-Hynes B, Nihal M, Zhong W and Ahmad N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem. 284:3823–3832. 2009.
28	Parsons RB, Aravindan S, Kadampeswaran A, et al: The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SH-SY5Y neuroblastoma cells against the toxicity of Complex I inhibitors. Biochem J. 436:145–155. 2011.
29	Ulanovskaya OA, Zuhl AM and Cravatt BF: NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 9:300–306. 2013.